01 May 2022: Clinical Research
Association Between Thromboelastography and Coronary Heart Disease
Liuqiao Yang 123ACDEF , Lei Ruan 4ABD , Yanping Zhao 235DE , Yueqi Lu 23CD , Ying Shan 23CD , Yucong Zhang 4B , Bangwei Chen 236C , Cuntai Zhang 4G* , Tao Li 23AE*DOI: 10.12659/MSM.935340
Med Sci Monit 2022; 28:e935340
Supplementary Table 3 Results of subgroup analyses after stratification for age, sex, medication of antiplatelet drug, and medication of lipid-lowering drug.
| Subgroup | No (%) of CHD patients | OR (95% CI) | p value for interaction |
|---|---|---|---|
| All parents | 49 (41.9%) | 1.11 (1.01–1.22) | |
| Age | 0.24 | ||
| 26 (48.1%) | 1.17 (1.03–1.34) | ||
| ≥60 | 23 (36.5%) | 1.04 (0.91–1.20) | |
| Sex | 0.19 | ||
| Male | 36 (41.3%) | 1.17 (1.04–1.32) | |
| Female | 13 (43.3%) | 1.01 (0.84–1.22) | |
| Antiplatelet drug | 0.19 | ||
| Yes | 19 (55.9%) | 1.28 (1.06–1.62) | |
| No | 30 (36.1%) | 1.09 (0.98–1.23) | |
| Lipid-lowering drug | 0.50 | ||
| Yes | 25 (49.0%) | 1.08 (0.96–1.24) | |
| No | 24 (36.4%) | 1.15 (1.02–1.33) | |
| CI – confidence interval; CHD – coronary heart disease; OR – odds ratio. | |||